Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FREQ NASDAQ:HOOK NASDAQ:ORPH NASDAQ:RDHL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFREQFrequency Therapeutics$0.30$0.58$0.18▼$16.00$10.94M0.84822,537 shs309,164 shsHOOKHOOKIPA Pharma$0.89-5.3%$0.90$0.72▼$4.32$10.85M1.04104,671 shs2,017 shsORPHOrphazyme A/S$1.43$0.51▼$77.77$30.72M1.681.37 million shs941,400 shsRDHLRedhill Biopharma$1.63$1.56$1.06▼$9.00$5.43M4.57556,149 shs30,017 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFREQFrequency Therapeutics0.00%0.00%0.00%0.00%0.00%HOOKHOOKIPA Pharma+4.91%+4.35%+1.25%-19.66%-74.66%ORPHOrphazyme A/S0.00%0.00%0.00%0.00%0.00%RDHLRedhill Biopharma-4.12%-18.09%+7.95%-14.66%-79.66%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFREQFrequency Therapeutics$0.30$0.58$0.18▼$16.00$10.94M0.84822,537 shs309,164 shsHOOKHOOKIPA Pharma$0.89-5.3%$0.90$0.72▼$4.32$10.85M1.04104,671 shs2,017 shsORPHOrphazyme A/S$1.43$0.51▼$77.77$30.72M1.681.37 million shs941,400 shsRDHLRedhill Biopharma$1.63$1.56$1.06▼$9.00$5.43M4.57556,149 shs30,017 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFREQFrequency Therapeutics0.00%0.00%0.00%0.00%0.00%HOOKHOOKIPA Pharma+4.91%+4.35%+1.25%-19.66%-74.66%ORPHOrphazyme A/S0.00%0.00%0.00%0.00%0.00%RDHLRedhill Biopharma-4.12%-18.09%+7.95%-14.66%-79.66%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFREQFrequency Therapeutics 0.00N/AN/AN/AHOOKHOOKIPA Pharma 2.33Hold$4.50405.62% UpsideORPHOrphazyme A/S 0.00N/AN/AN/ARDHLRedhill Biopharma 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest FREQ, RDHL, HOOK, and ORPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025RDHLRedhill BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025RDHLRedhill BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFREQFrequency Therapeutics$14.07M0.78N/AN/A$1.96 per share0.15HOOKHOOKIPA Pharma$9.35M1.16N/AN/A$4.25 per share0.21ORPHOrphazyme A/SN/AN/AN/AN/A$2.74 per shareN/ARDHLRedhill Biopharma$8.04M0.68N/AN/A($3.66) per share-0.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFREQFrequency Therapeutics-$81.58M-$1.89N/AN/AN/AN/A-107.67%-61.40%N/AHOOKHOOKIPA Pharma-$43.50M-$4.73N/AN/AN/A-785.66%-120.09%-77.14%11/12/2025 (Estimated)ORPHOrphazyme A/S-$97.01MN/A0.00N/AN/AN/AN/AN/AN/ARDHLRedhill Biopharma-$8.27MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFREQFrequency TherapeuticsN/AN/AN/AN/AN/AHOOKHOOKIPA PharmaN/AN/AN/AN/AN/AORPHOrphazyme A/SN/AN/AN/AN/AN/ARDHLRedhill BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFREQFrequency TherapeuticsN/A5.815.81HOOKHOOKIPA PharmaN/A3.613.61ORPHOrphazyme A/S0.141.80N/ARDHLRedhill BiopharmaN/A0.560.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFREQFrequency Therapeutics13.18%HOOKHOOKIPA Pharma63.88%ORPHOrphazyme A/S10.74%RDHLRedhill Biopharma7.20%Insider OwnershipCompanyInsider OwnershipFREQFrequency Therapeutics16.80%HOOKHOOKIPA Pharma3.30%ORPHOrphazyme A/SN/ARDHLRedhill Biopharma6.81%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFREQFrequency Therapeutics4636.52 million30.39 millionNot OptionableHOOKHOOKIPA Pharma16012.19 million11.79 millionOptionableORPHOrphazyme A/S14135.31 millionN/ANot OptionableRDHLRedhill Biopharma2103.33 million3.10 millionNo DataFREQ, RDHL, HOOK, and ORPH HeadlinesRecent News About These CompaniesRedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®October 6, 2025 | prnewswire.comRedHill Biopharma wins New York Supreme Court appealSeptember 29, 2025 | msn.comRedHill Biopharma stock surges after court upholds $10M judgmentSeptember 29, 2025 | investing.comRedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against KukboSeptember 29, 2025 | prnewswire.comRedHill Biopharma Announces First Half 2025 Financial Results and Operational HighlightsSeptember 5, 2025 | prnewswire.comRedHill awarded $1.82M in legal costs and expenses in action against KukboAugust 20, 2025 | msn.comRedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment WinAugust 20, 2025 | prnewswire.comRedHill Biopharma receives Talicia licensing payments totaling $1.1MAugust 19, 2025 | msn.comRedHill Received Talicia® Licensing Payments Totaling $1.1 MillionAugust 18, 2025 | prnewswire.comRedHill Biopharma Granted Nasdaq Compliance ExtensionAugust 14, 2025 | msn.comRedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's DiseaseJuly 21, 2025 | prnewswire.comRDHL - Redhill Biopharma Ltd ADR Trailing Returns - MorningstarJuly 18, 2025 | morningstar.comMRedHill initiates recruitment for expanded Phase 2 opaganib/darolutamide studyJuly 2, 2025 | msn.comRedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate CancerJuly 1, 2025 | prnewswire.comRedHill Biopharma Ltd. (RDHL) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRedHill Biopharma Ltd. (RDHL) Income Statement - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment WinMay 13, 2025 | prnewswire.comRedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology CongressMay 2, 2025 | prnewswire.comRedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107April 28, 2025 | prnewswire.comRedHill Biopharma receives non-compliance letter from NasdaqApril 18, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFREQ, RDHL, HOOK, and ORPH Company DescriptionsFrequency Therapeutics NASDAQ:FREQFrequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.HOOKIPA Pharma NASDAQ:HOOK$0.89 -0.05 (-5.32%) As of 10:36 AM EasternHOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Orphazyme A/S NASDAQ:ORPHOrphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.Redhill Biopharma NASDAQ:RDHL$1.63 0.00 (0.00%) As of 11:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
